YolTech Announces Licensing Agreement with Salubris for the Development and Commercialization of YOLT-101 in Mainland China
- Written by PR Newswire
SHANGHAI, Aug. 27, 2024 /PRNewswire/ -- YolTech Therapeutics, a pioneering clinical-stage gene editing company dedicated to delivering lifelong cures, announced today that it has entered into an exclusive licensing agreement with Salubris Pharmaceuticals Co., Ltd. (stock code: 002294.SZ), a leading pharmaceutical company established in 1998 and...
